EGFR and non-small cell lung carcinoma: Unfortunately, due to the inhibition of antitumor immune response by EGFR signaling, ICIs treatment of NSCLC patients with EGFR alterations failed to show clinical benefits, especially for those with T790M mutation [11, 12].